Ovid Therapeutics (OVID) Deferred Taxes (2016 - 2017)

Ovid Therapeutics (OVID) posted Deferred Taxes of $725657.0 for Q3 2017, up 6.49% on a QoQ basis from $681458.0 in Q2 2017.

Ovid Therapeutics (OVID) Deferred Taxes (2016 - 2017) Analysis & Trends

Ovid Therapeutics' Deferred Taxes history runs 2 years deep, the most recent figure standing at $725657.0 for Q3 2017.

Quarterly Deferred Taxes changed N/A year-over-year to $725657.0 in Q3 2017, while the trailing twelve-month figure through Dec 2017 was $229000.0 (changed N/A YoY) and the FY2017 annual result came in at $229000.0, up 200.0% from the prior year.
Deferred Taxes was $725657.0 for Q3 2017 at Ovid Therapeutics, up from $681458.0 in the prior quarter.
Across five years, Deferred Taxes topped out at $725657.0 in Q3 2017 and bottomed at -$1.2 million in Q1 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Deferred Taxes (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-859,000.00
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn	-
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn	-65.30 Mn
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn	96.00 Mn
7	Belite Bio	62.72 Bn	62.72 Bn	-	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn	-
9	Revolution Medicines	37.35 Bn	37.35 Bn	-	-
10	Ovid Therapeutics	118.66 Mn	-36.86 Mn	-	-

Download Data